Double blind trial of a deuterated form of linoleic acid (RT001) in Friedreich ataxia

The paper describes the outcomes from a clinical trial for Friedreich ataxia (the most common hereditary ataxia impacting walking, talking, heart and brain health). The trial did not show treatment efficacy.


Redenlab was the speech biomarker provider on the trial with Retrotope.

Click here to find out more.

Related Post

Repetition Assessment for Speech and Language Disorders: A Study of the Logopenic Variant of Primary Progressive Aphasia

  • Posted on 10 March, 2023
    Primary Progressive Aphasia is a type of young onset dementia that is characterised by language impairment. Measuring disease progression and...
    Read more

    Adults with a history of recreational cannabis use have altered speech production

    • Posted on 10 March, 2023
      Stereotypical depictions of speech in cannabis users often suggest slow, laboured output, yet objective evidence supporting this assumption is extremely...
      Read more

      Perceptual and Acoustic Analysis of Speech in Spinocerebellar ataxia Type 1

      • Posted on 10 March, 2023
        Speech is a cardinal and important feature of ataxia. We have put together a comprehensive description of dysarthria in spinocerebellar...
        Read more